DRUG · Unmapped registry intervention
Bemcentinib; pembrolizumab
Find medicine records ·
Find other trials using this name
Clinical trial
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
NCT03184558
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedBemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Triple Negative Breast Cancerunresolved
Inflammatory Breast Cancer Stage IVunresolved
Interventions
Sponsors & collaborators
BerGenBio ASAlead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
MadridSpain2BarcelonaSpain2LondonUnited Kingdom1PittsburghPennsylvania, United States1San DiegoCalifornia, United States1Kansas CityMissouri, United States1ManchesterUnited Kingdom1DuarteCalifornia, United States1LebanonNew Hampshire, United States1ZaragozaSpain1NottinghamUnited Kingdom1AlicanteSpain1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03184558 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.